Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIF plus dasatinib and conventional chemotherapy in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
ChiCTR1900026847Phase 4Not yet recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Compound Huangdai Tablet and dasatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Event-free survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
Compound Huangdai Tabletdasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR1900026847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026847.